Category: Research & Development
Global Research & Development
-
Cannabis Edibles
... CAGR of 22.0% over the analysis period 2024-2030. Solid Edibles, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$38.2 Billion by the end of the analysis ... Read More
-
Pharmaceutical Contract Manufacturing
... at a CAGR of 5.2% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$93.8 Billion by the end of the ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Melanoma Therapeutics
... CAGR of 13.7% over the analysis period 2024-2030. Cutaneous Melanoma, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$4.3 Billion by the end of the analysis ... Read More
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Nanocatalysts
... 6.6% over the analysis period 2024-2030. Refinery & Petrochemicals, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.8 Billion by the end of the analysis period. ... Read More
-
Orphan Drugs
... CAGR of 12.0% over the analysis period 2024-2030. Biologic Drugs, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$308.5 Billion by the end of the analysis ... Read More
-
Lymphoma Therapeutics
... CAGR of 6.5% over the analysis period 2024-2030. Non-Hodgkin Lymphoma (NHL), one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$20.5 Billion by the end of the ... Read More
-
Rheumatoid Arthritis Diagnosis Tests
... 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Diagnostic Laboratories End-Use, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$478.3 Million by ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
-
HIV Drugs
... CAGR of 5.2% over the analysis period 2024-2030. Combination HIV Medicines, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$29.0 Billion by the end of the ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Rheumatoid Arthritis Therapeutics
... at a CAGR of 4.1% over the analysis period 2024-2030. Pharmaceuticals, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$28.0 Billion by the end of the ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Neurodegenerative Drugs
... CAGR of 6.8% over the analysis period 2024-2030. Dopamine Agonist, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.7 Billion by the end of the analysis ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
Testosterone Replacement Therapy (TRT)
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. TRT Injectables, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.6 Billion by the ... Read More
-
Cancer Therapies
... CAGR of 10.4% over the analysis period 2024-2030. Blood Cancer, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$119.2 Billion by the end of the analysis ... Read More
-
Contract Research Outsourcing
... at a CAGR of 7.9% over the analysis period 2024-2030. Clinical, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$61.2 Billion by the end of the ... Read More
-
e-Clinical Trial Technologies
... at a CAGR of 13.1% over the analysis period 2024-2030. Clinical Trial Management Systems (CTMS), one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$9.9 Billion by ... Read More
-
Acne Drugs
... CAGR of 6.9% over the analysis period 2024-2030. Inflammatory, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$9.6 Billion by the end of the analysis period. ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC), one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by the ... Read More
-
Immunotherapy Drugs
... CAGR of 9.6% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$254.4 Billion by the end of the analysis ... Read More
-
Freeze and Thaw Systems Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
... equips stakeholders with a detailed overview of the market landscape to support informed decision-making. Key Insights: Freeze and Thaw Systems Market Size (2025E): US$ 412.4 million Projected Market Value (2032F): US$ 645.1 million Global Market ... Read More
Research Assistance
